Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$176.37 USD
-1.88 (-1.05%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $176.31 -0.06 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BDX 176.37 -1.88(-1.05%)
Will BDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDX
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BD Partners With Waters to Build High-Volume Diagnostics Leader
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Top Stock Reports for Amazon.com, Home Depot & Cisco Systems
Other News for BDX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
BDX Unveils At-Home HPV Test to Revolutionize Cervical Cancer Screening | BDX stock news
BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening ...
BDX Gains FDA Approval for BD Veritor System to Detect COVID-19 Antigens
BD gets FDA nod for rapid COVID-19 test